Yarrow Bioscience, Inc. (YARW)
NASDAQ: YARW · Real-Time Price · USD
30.21
+1.36 (4.71%)
At close: Sep 4, 2026, 4:00 PM EDT
28.80
-1.41 (-4.67%)
After-hours: Sep 4, 2026, 7:30 PM EDT
Yarrow Bioscience Employees
Yarrow Bioscience had 7 employees as of June 30, 2026.
Employees
7
Change
n/a
Growth
n/a
Revenue / Employee
n/a
Profits / Employee
-$40,568,000
Market Cap
84.59M
Employees Chart
| Date | Employees | Change (1Y) | Growth (1Y) |
|---|---|---|---|
| Jun 30, 2026 | 7 | - | - |
| Mar 31, 2026 | 6 | - | - |
Related Stocks
| Company Name | Employees |
|---|---|
| Gossamer Bio | 162 |
| ImmuCell | 73 |
| Cardiff Oncology | 31 |
| iBio, Inc. | 20 |
| MAIA Biotechnology | 13 |
| Rallybio | 7 |
| MediciNova | 6 |
| Aldeyra Therapeutics | 6 |
YARW News
- 21 days ago - Yarrow Bioscience reported Q2 EPS ($2.14) - TheFly
- 25 days ago - Yarrow Bioscience Reports Second Quarter 2026 Financial Results and Provides Business Update - Business Wire
- 5 weeks ago - Yarrow Bioscience initiated with a Buy at BTIG - TheFly
- 5 weeks ago - Yarrow Bioscience initiated with a Buy at TD Cowen - TheFly
- 6 weeks ago - Yarrow Bioscience Announces Closing of Merger with VYNE Therapeutics and Initiation of Dosing in Phase 2a/2b Trial of YB-101, a Potential First-in-Class Treatment for Graves' Disease and Thyroid Eye Disease - Business Wire
- 6 weeks ago - VYNE Therapeutics Provides Update Regarding Cash Dividend, Reverse Stock Split and Anticipated Timing of Closing of the Proposed Merger with Yarrow Bioscience - GlobeNewsWire
- 6 weeks ago - VYNE Therapeutics Announces 1-for-50 Reverse Stock Split and Provides Update Regarding Special Dividend in Connection with the Proposed Merger with Yarrow Bioscience - GlobeNewsWire
- 1 month ago - VYNE Therapeutics Declares Special Cash Dividend in Connection with the Proposed Merger with Yarrow Bioscience - GlobeNewsWire